Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.
Leroy R, Silversmit G, Bourgeois J, De Gendt C, Savoye I, Verbeeck J, Van Damme N, Stordeur S, Canon JL, Carly B, Cusumano PG, de Azambuja E, De Visschere P, Decloedt J, Desreux J, Duhoux FP, Taylor D, van Dam P, Vanhoutte I, Veldeman L, Wildiers H. Leroy R, et al. Among authors: van dam p. Eur J Cancer. 2024 Oct;210:114232. doi: 10.1016/j.ejca.2024.114232. Epub 2024 Jul 20. Eur J Cancer. 2024. PMID: 39236426
Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database.
Garcia-Etienne CA, Tomatis M, Heil J, Friedrichs K, Kreienberg R, Denk A, Kiechle M, Lorenz-Salehi F, Kimmig R, Emons G, Danaei M, Heyl V, Heindrichs U, Rageth CJ, Janni W, Marotti L, del Turco MR, Ponti A; eusomaDB Working Group. Garcia-Etienne CA, et al. Eur J Cancer. 2012 Sep;48(13):1947-56. doi: 10.1016/j.ejca.2012.03.008. Epub 2012 Apr 4. Eur J Cancer. 2012. PMID: 22483323
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).
Aronson SL, Walker C, Thijssen B, van de Vijver KK, Horlings HM, Sanders J, Alkemade M, Koole SN, Lopez-Yurda M, Lok CAR; OVHIPEC-1 Study Group; Rottenberg S, van Rheenen J, Sonke GS, van Driel WJ, Kester LA, Hahn K. Aronson SL, et al. Br J Cancer. 2024 Aug;131(3):565-576. doi: 10.1038/s41416-024-02731-6. Epub 2024 Jun 12. Br J Cancer. 2024. PMID: 38866963 Free article.
An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study).
Trozzi R, Tuyaerts S, Annibali D, Herreros Pomares A, Boog L, Van Dam P, Leunen K, Deroose C, Trum H, Amant F. Trozzi R, et al. Among authors: van dam p. Int J Gynecol Cancer. 2024 Aug 5;34(8):1217-1224. doi: 10.1136/ijgc-2023-005229. Int J Gynecol Cancer. 2024. PMID: 38724237 Clinical Trial.
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG); Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO); Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO); National Cancer Research Institute (NCRI); Australia New Zealand Gynaecological Oncology Group (ANZGOG); Mario Negri Gynecologic Oncology group (MaNGO). Despierre E, et al. Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6. Target Oncol. 2015. PMID: 26004768 Free PMC article. Clinical Trial.
His bundle pacing in a patient with complete atrioventricular block and congenitally corrected transposition of the great arteries: potential of the use of extended reality and cardiac electrical activity projected into 3D heart model.
Matusik PT, Szotek M, Komar M, van Dam P, Czunko A, Proniewska KK. Matusik PT, et al. Among authors: van dam p. Pol Arch Intern Med. 2024 Oct 3:16856. doi: 10.20452/pamw.16856. Online ahead of print. Pol Arch Intern Med. 2024. PMID: 39365174 Free article. No abstract available.
Fibroblast Activation Protein-α and the Immune Landscape: Unraveling T1 Non-muscle-invasive Bladder Cancer Progression.
Muilwijk T, Baekelandt L, Akand M, Daelemans S, Marien K, Waumans Y, van Dam PJ, Kockx M, Van den Broeck T, Van Cleynenbreugel B, Van der Aa F, Gevaert T, Joniau S. Muilwijk T, et al. Among authors: van dam pj. Eur Urol Open Sci. 2024 Jul 1;66:67-74. doi: 10.1016/j.euros.2024.06.011. eCollection 2024 Aug. Eur Urol Open Sci. 2024. PMID: 39044944 Free PMC article.
Long-term effects of the COVID-19 pandemic for patients with cancer.
Debie Y, Palte Z, Salman H, Verbruggen L, Vanhoutte G, Chhajlani S, Raats S, Roelant E, Vandamme T, Peeters M, van Dam PA. Debie Y, et al. Among authors: van dam pa. Qual Life Res. 2024 Oct;33(10):2845-2853. doi: 10.1007/s11136-024-03726-9. Epub 2024 Jul 3. Qual Life Res. 2024. PMID: 38961007 Free PMC article.
411 results